Pharmacogenetics and pharmacogenomics lec-11

Genomics:study of genetic material found in a cell

- •Pharmacogenomics: is a branch of pharmacology concerned with using DNA data to explain individual variations in drug response.
- Pharmacogenetics: The study or clinical testing of genetic variation affecting individual patients different response to drugs "Using genomic data"

•Goal: personalized medicine Personalized medicine: the tailoring of medical treatment to the specific characteristics of each patient. الدوا المناسب للشخص المناسب

Genetic polymorphism 1% '1gene=multiple phenotypes"	SNPs (Single Nucleotide Polymorphisms) m/c	Indels (Insertions/Deletions)	
Definition	Single base substitution in DNA sequence.	Addition or deletion of bases in the genome.	Phenotype
Types	 Silent: no amino acid change Missense: amino acid change affects protein function(malfunction) Nonsense: creates a stop codon, producing a nonfunctional protein 		genotype b b b B B b B b b b b b b b b b b b b b
Examples	 SNP in non-coding region may increase cancer risk Missense mutation in CFTR gene linked to cystic fibrosis 	Indel mutation associated with Bloom syndrome in jerwish,japanese	Phenotype: الصغة الظاهر The phenotype is determined by genotype.

10VA

Examples of polymorphism: Pharmacokinetcs

Drug/Condition	Gene/Protein Involved	Variation Type	Impact	
Clopidogrel	15% from drug metabolized into <u>active form</u> by CYP2C19 (NOTE: 85% by esterase)	Pharmacokinetic	Poor metabolizers have reduced anticoagulant effect, risking clotting.	
Antidepressants	CYP2D6	Pharmacokinetic	Poor metabolizers have increased drug toxicity; ultra-rapid metabolizers may have decreased efficacy.	حفظ مهم
Succinylcholine Tx: fresh blood transfusion(imp)	Butyrylcholinesterase (BCHE) also known as plasma cholinesterase or pseudocholinesterase)	Pharmacokinetic	Mutations can cause prolonged muscle paralysis and respiratory failure (scoline apnea).	Most important enzymes of CYP450 family are
Isoniazid (INH)	N-acetyltransferase 2 (NAT2)	Pharmacokinetic	Slow acetylators have increased risk of hepatotoxicity ; rapid acetylators have decreased drug efficacy.	CYP3A4 CYP2C9 CYP2C19 CYP2D6



Pharmacodynamics and disease modifying examples:

G6PD protect RBCs against oxidizing agents: antibiotics,fava beans,aspirin,chl oroquineetc	Beta Receptor Drugs	Beta-adrenergic receptor genes	Pharmacodynamic	Tachyphylaxsis – like in salbutamol
	Some antidepressants that target serotonin	Serotonin receptor genes	Pharmacodynamic	Variations affect antidepressant efficacy and patient response.
MH occur Due to genetic mutations in RYR1 gene response to particular medications used during general anesthesia (volatile anesthetic agents and succinylcholine) (RYR1): functions as calcium release channel in the sarcoplasmic	G6PD Deficiency (Fauvism) More in males	G6PD enzyme	Disease-modifying	Deficiency leads to hemolysis, anemia when exposed to oxidizing agents. Life threatining
	Malignant Hyperthermia Tx:Dantrolene(imp) (Dantrolene antagonize RYR1)	RYR1 (Ca release channel)	Disease-modifying	Susceptibility to severe reaction during anesthesia; causes muscle rigidity, fever,tachycardia,metabolic acidosis and Complications like muscle breakdown and high blood pottasium
reticulum				

Good luck 🙂

Created by :Dr.Farah breik